Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. I...
Saved in:
| Published in: | Gut and liver Vol. 13; no. 6; pp. 604 - 616 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
Korea (South)
Editorial Office of Gut and Liver
15.11.2019
Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Subjects: | |
| ISSN: | 1976-2283, 2005-1212, 2005-1212 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options. |
|---|---|
| AbstractList | New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options. New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-totarget algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options. KCI Citation Count: 2 New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options.New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options. |
| Author | Moon, Won |
| AuthorAffiliation | 1 Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea 2 Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea |
| AuthorAffiliation_xml | – name: 2 Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea – name: 1 Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea |
| Author_xml | – sequence: 2 givenname: Won orcidid: 0000-0002-3963-8680 surname: Moon fullname: Moon, Won organization: Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31195433$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002522833$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNplkk1vEzEQhi1URNOCxC9Ae4TDFo-_dn1BKqFARAUIhbPl9Udwu7sO9iZV_z1u0hQqTpbGzzyvNZ4TdDTG0SH0EvAZx1i-XY09SAzyCZoRjHkNBMgRmoFsRE1IS4_RSc5XGAsgDX-GjimA5IzSGfry3aW8dmYKW5erOFbzTUpunCo92upr3Lq-Wianp6HUcuVjqhaj7_Uw6Cmm2-p9vCnEh5Cdzu45eup1n92L-_MU_fx4sZx_ri-_fVrMzy9rwxoy1Y3umOTCy9azjmignWtEJzhwwbvOC2istZww37UNcdRiAp4JabzAhgB19BS92XvH5NW1CSrqsDtXUV0ndf5juVCCQCsFLexiz9qor9Q6hUGn213DrhDTSuk0BdM71TpKLGUS2zIb61lrtWm4Z0C15hxEcb3bu9abbnDWlJEk3T-SPr4Zw6_ypq0SrcCYsiJ4fS9I8ffG5UkNIRvX93p0cZMVocB4wwFDQV_9m_UQcvi5ApztAZNizsl5ZcKkpxDvokOvAKu71VCH1fgb_tBwcP6H_gGZBbhQ |
| CitedBy_id | crossref_primary_10_1016_j_cyto_2022_155890 crossref_primary_10_3892_ijmm_2023_5256 crossref_primary_10_1080_19490976_2024_2380064 crossref_primary_10_3389_fphar_2021_705325 crossref_primary_10_3390_ijerph17145120 crossref_primary_10_1080_1744666X_2024_2400300 crossref_primary_10_1080_87559129_2023_2273929 crossref_primary_10_3389_fimmu_2022_1074271 crossref_primary_10_1089_can_2020_0109 crossref_primary_10_1093_ecco_jcc_jjad011 crossref_primary_10_3389_fphar_2024_1496068 crossref_primary_10_1186_s13020_021_00553_9 crossref_primary_10_1017_S0022149X25100345 crossref_primary_10_3390_ijms24108695 crossref_primary_10_3390_nu15234993 crossref_primary_10_3390_antiox13111369 crossref_primary_10_1093_ibd_izab190 crossref_primary_10_14309_ajg_0000000000000709 crossref_primary_10_1016_j_lfs_2024_122638 crossref_primary_10_1039_D0FO03061A crossref_primary_10_1111_jam_15681 crossref_primary_10_1016_j_mtbio_2025_102058 crossref_primary_10_1097_MD_0000000000025340 crossref_primary_10_3904_kjim_2022_152 crossref_primary_10_1128_Spectrum_01369_21 crossref_primary_10_1128_spectrum_00657_22 crossref_primary_10_3389_fphar_2024_1481678 crossref_primary_10_1007_s00011_023_01691_6 crossref_primary_10_1002_iub_2564 crossref_primary_10_1021_acsami_5c13154 crossref_primary_10_1016_j_apmt_2024_102078 crossref_primary_10_1016_j_intimp_2024_111527 crossref_primary_10_3389_fmicb_2023_1228778 crossref_primary_10_1136_egastro_2023_100055 crossref_primary_10_3389_fphys_2021_662739 crossref_primary_10_1007_s13555_023_01081_0 crossref_primary_10_1186_s12889_024_17758_w crossref_primary_10_1002_adhm_202304674 crossref_primary_10_1007_s10787_023_01226_9 crossref_primary_10_1177_00368504241253709 crossref_primary_10_1093_jcag_gwad032 crossref_primary_10_1186_s43088_023_00340_5 crossref_primary_10_3390_nu15081845 crossref_primary_10_3928_19382359_20230720_04 crossref_primary_10_1016_j_bbi_2023_06_003 crossref_primary_10_4291_wjgp_v11_i6_114 crossref_primary_10_3390_ijms23158494 crossref_primary_10_1016_j_matdes_2022_110686 crossref_primary_10_1038_s41598_025_91358_5 crossref_primary_10_3390_ph16111581 crossref_primary_10_1093_ibd_izae031 crossref_primary_10_2147_JIR_S492079 crossref_primary_10_1097_MCG_0000000000001583 crossref_primary_10_2147_JIR_S348079 crossref_primary_10_1186_s12876_023_02993_z crossref_primary_10_3390_biologics1020012 crossref_primary_10_1007_s10620_022_07382_2 crossref_primary_10_1002_imt2_136 crossref_primary_10_3390_ijms26136465 crossref_primary_10_1007_s13679_023_00506_3 crossref_primary_10_1177_1759720X20969261 crossref_primary_10_3390_jcm10245984 crossref_primary_10_1002_jcla_24455 crossref_primary_10_1002_jcla_24699 crossref_primary_10_3389_fphar_2022_1008976 crossref_primary_10_3389_fsurg_2022_882625 crossref_primary_10_3389_fimmu_2022_944982 crossref_primary_10_3389_fimmu_2022_1045901 crossref_primary_10_20900_immunometab20220006 crossref_primary_10_1148_rg_210146 crossref_primary_10_1016_j_heliyon_2024_e25357 crossref_primary_10_1016_j_dld_2020_10_040 crossref_primary_10_1111_1440_1681_13468 crossref_primary_10_1186_s12929_023_00983_7 crossref_primary_10_3892_mmr_2025_13606 crossref_primary_10_3389_fimmu_2021_761981 crossref_primary_10_1097_MEG_0000000000003068 crossref_primary_10_3389_fnut_2025_1494351 crossref_primary_10_1007_s12325_020_01366_2 crossref_primary_10_3389_fbioe_2021_635764 crossref_primary_10_3390_ijms24031954 crossref_primary_10_3390_molecules27217622 crossref_primary_10_1016_j_intimp_2024_112380 crossref_primary_10_1007_s13346_024_01736_1 crossref_primary_10_1128_spectrum_01457_23 crossref_primary_10_1016_j_jprot_2025_105455 crossref_primary_10_3390_nu12123635 crossref_primary_10_3390_ph17030283 crossref_primary_10_1007_s10620_022_07517_5 crossref_primary_10_4103_sjg_sjg_277_22 crossref_primary_10_1093_ibd_izab334 crossref_primary_10_1186_s12859_021_04016_8 crossref_primary_10_3389_fcimb_2022_1028899 crossref_primary_10_3390_ph14070637 crossref_primary_10_1016_j_bbadis_2024_167648 crossref_primary_10_3390_nu15010031 crossref_primary_10_1017_S0022149X24000191 crossref_primary_10_3389_fimmu_2021_642166 crossref_primary_10_1016_j_phymed_2021_153709 crossref_primary_10_3390_ph18040478 crossref_primary_10_2147_CLEP_S402718 crossref_primary_10_1038_s41598_023_36020_8 |
| Cites_doi | 10.1093/ecco-jcc/jjx180.004 10.3748/wjg.v20.i43.16014 10.1038/ajg.2014.183 10.1056/NEJMoa1215739 10.1038/s41395-018-0296-0 10.5599/admet.4.1.276 10.1056/NEJMoa1606910 10.1093/ecco-jcc/jjw152 10.1097/01.MIB.0000194183.92671.b6 10.1056/NEJMoa033402 10.1053/j.gastro.2011.10.032 10.4049/jimmunol.178.5.2623 10.2174/13894501113149990157 10.4049/jimmunol.150.8.3459 10.1136/gut.2006.106781 10.1002/jcb.20127 10.1016/j.cgh.2016.08.044 10.1093/ecco-jcc/jjw177 10.1002/ibd.20014 10.1111/apt.13970 10.1111/apt.12639 10.1038/nri1226 10.1038/nchembio.173 10.1046/j.1365-2036.2002.01205.x 10.1016/j.cgh.2018.11.035 10.1053/j.gastro.2011.02.045 10.1016/S0140-6736(17)30930-3 10.1016/j.cgh.2009.01.004 10.1111/apt.14631 10.1097/MOG.0000000000000078 10.1053/j.gastro.2007.03.024 10.1111/j.1365-2036.2011.04612.x 10.1002/14651858.CD000478.pub4 10.1016/j.tips.2013.05.002 10.1038/ajg.2013.4 10.4161/mabs.3.6.17815 10.1053/j.gastro.2008.01.012 10.1056/NEJM199710093371502 10.1016/S2468-1253(18)30233-4 10.1056/NEJMoa1205037 10.1136/gutjnl-2016-313457 10.1016/j.crohns.2010.04.004 10.1097/MIB.0000000000000979 10.1016/S0016-5085(17)34357-3 10.1136/gutjnl-2018-BSGAbstracts.106 10.1056/NEJMoa050516 10.1111/bph.13476 10.1016/S0140-6736(16)32537-5 10.1016/S0140-6736(02)08512-4 10.1016/j.cgh.2014.01.029 10.1038/ajg.2010.392 10.5217/ir.2017.15.4.475 10.1016/j.autrev.2017.03.007 10.2174/13894501113146660206 10.1136/gutjnl-2016-312912 10.3389/fimmu.2017.00891 10.1056/NEJMoa1215734 10.1056/NEJMoa051782 10.1056/NEJMoa1513248 10.1111/bjd.12214 10.1016/S0140-6736(89)91183-5 10.1002/14651858.CD000067.pub3 10.1016/S0140-6736(14)60661-9 10.1111/j.1600-065X.2008.00754.x 10.1080/14712598.2016.1177019 10.1053/j.gastro.2005.11.030 10.1136/gut.2010.221127 10.1111/apt.14794 10.1053/j.gastro.2013.10.052 10.1053/j.gastro.2006.09.016 10.1001/archneur.65.12.noc80051 10.1136/gutjnl-2015-311079 10.1016/j.semarthrit.2016.05.014 10.3390/ijms18061276 10.1016/S0140-6736(16)31203-X 10.4166/kjg.2018.71.2.61 10.1016/j.jneuroim.2013.08.011 10.1056/NEJMoa062897 10.1172/JCI12821 10.1111/jdv.13611 10.1136/gutjnl-2016-312735 10.1136/gut.2010.226548 10.1016/j.cgh.2018.02.024 10.1001/jama.2015.16700 10.1056/NEJMoa043335 10.1093/ecco-jcc/jjx063 10.1056/NEJMoa1602773 10.1016/S0140-6736(17)30570-6 10.1056/NEJMoa1107829 10.1053/j.gastro.2014.05.008 10.1097/MIB.0000000000001228 10.1093/ecco-jcc/jjw176 10.1056/NEJMoa051847 10.1056/NEJMoa1407250 10.1056/NEJMoa0904492 10.1053/j.gastro.2017.03.049 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. 2019 |
| Copyright_xml | – notice: Copyright © 2019 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA ACYCR |
| DOI | 10.5009/gnl19019 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-1212 |
| EndPage | 616 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_6218963 oai_doaj_org_article_8e32d3490d954df48dac75f413aa5516 PMC6860034 31195433 10_5009_gnl19019 |
| Genre | Journal Article Review |
| GroupedDBID | --- 5-W 8JR AAKDD AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P GROUPED_DOAJ GX1 HYE HZB OK1 RPM 9ZL CGR CUY CVF ECM EIF NPM 7X8 5PM 53G |
| ID | FETCH-LOGICAL-c472t-7ab4956f98f4b2a13be76b651565bbf617ddd524fb872e3d021f469cf60c213e3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 108 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000496945500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1976-2283 2005-1212 |
| IngestDate | Sun Mar 09 07:50:58 EDT 2025 Mon Nov 10 04:23:45 EST 2025 Tue Nov 04 01:53:01 EST 2025 Sun Nov 09 04:45:25 EST 2025 Thu Apr 03 06:59:08 EDT 2025 Sat Nov 29 01:46:42 EST 2025 Tue Nov 18 22:40:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Crohn disease Therapy Inflammatory bowel diseases Colitis, ulcerative |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c472t-7ab4956f98f4b2a13be76b651565bbf617ddd524fb872e3d021f469cf60c213e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-3963-8680 |
| OpenAccessLink | https://doaj.org/article/8e32d3490d954df48dac75f413aa5516 |
| PMID | 31195433 |
| PQID | 2314575101 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_6218963 doaj_primary_oai_doaj_org_article_8e32d3490d954df48dac75f413aa5516 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6860034 proquest_miscellaneous_2314575101 pubmed_primary_31195433 crossref_citationtrail_10_5009_gnl19019 crossref_primary_10_5009_gnl19019 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-15 |
| PublicationDateYYYYMMDD | 2019-11-15 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Gut and liver |
| PublicationTitleAlternate | Gut Liver |
| PublicationYear | 2019 |
| Publisher | Editorial Office of Gut and Liver Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Publisher_xml | – name: Editorial Office of Gut and Liver – name: Gastroenterology Council for Gut and Liver – name: 거트앤리버 소화기연관학회협의회 |
| References | ref57 ref56 ref59 ref58 ref53 ref52 ref55 ref54 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref100 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref13 ref12 ref15 ref14 ref97 ref96 ref11 ref99 ref10 ref98 ref17 ref16 ref19 ref18 ref93 ref92 ref95 ref94 ref91 ref90 ref89 ref86 ref85 ref88 ref87 ref82 ref81 ref84 ref83 ref80 ref79 ref78 ref75 ref74 ref77 ref76 ref2 ref1 ref71 ref70 ref73 ref72 ref68 ref67 ref69 ref64 ref63 ref66 ref65 ref60 ref62 ref61 |
| References_xml | – ident: ref78 doi: 10.1093/ecco-jcc/jjx180.004 – ident: ref17 doi: 10.3748/wjg.v20.i43.16014 – ident: ref85 – ident: ref10 doi: 10.1038/ajg.2014.183 – ident: ref33 doi: 10.1056/NEJMoa1215739 – ident: ref86 doi: 10.1038/s41395-018-0296-0 – ident: ref19 doi: 10.5599/admet.4.1.276 – ident: ref54 doi: 10.1056/NEJMoa1606910 – ident: ref89 doi: 10.1093/ecco-jcc/jjw152 – ident: ref42 doi: 10.1097/01.MIB.0000194183.92671.b6 – ident: ref69 doi: 10.1056/NEJMoa033402 – ident: ref4 doi: 10.1053/j.gastro.2011.10.032 – ident: ref51 doi: 10.4049/jimmunol.178.5.2623 – ident: ref73 doi: 10.2174/13894501113149990157 – ident: ref60 doi: 10.4049/jimmunol.150.8.3459 – ident: ref11 doi: 10.1136/gut.2006.106781 – ident: ref79 doi: 10.1002/jcb.20127 – ident: ref35 doi: 10.1016/j.cgh.2016.08.044 – ident: ref37 doi: 10.1093/ecco-jcc/jjw177 – ident: ref90 doi: 10.1002/ibd.20014 – ident: ref9 doi: 10.1111/apt.13970 – ident: ref23 doi: 10.1111/apt.12639 – ident: ref50 doi: 10.1038/nri1226 – ident: ref81 doi: 10.1038/nchembio.173 – ident: ref31 doi: 10.1046/j.1365-2036.2002.01205.x – ident: ref55 doi: 10.1016/j.cgh.2018.11.035 – ident: ref1 doi: 10.1053/j.gastro.2011.02.045 – ident: ref64 doi: 10.1016/S0140-6736(17)30930-3 – ident: ref18 doi: 10.1016/j.cgh.2009.01.004 – ident: ref59 doi: 10.1111/apt.14631 – ident: ref8 doi: 10.1097/MOG.0000000000000078 – ident: ref26 doi: 10.1053/j.gastro.2007.03.024 – ident: ref15 doi: 10.1111/j.1365-2036.2011.04612.x – ident: ref21 doi: 10.1002/14651858.CD000478.pub4 – ident: ref82 doi: 10.1016/j.tips.2013.05.002 – ident: ref93 doi: 10.1038/ajg.2013.4 – ident: ref41 doi: 10.4161/mabs.3.6.17815 – ident: ref16 doi: 10.1053/j.gastro.2008.01.012 – ident: ref5 doi: 10.1056/NEJM199710093371502 – ident: ref67 doi: 10.1016/S2468-1253(18)30233-4 – ident: ref92 doi: 10.1056/NEJMoa1205037 – ident: ref65 doi: 10.1136/gutjnl-2016-313457 – ident: ref13 doi: 10.1016/j.crohns.2010.04.004 – ident: ref36 doi: 10.1097/MIB.0000000000000979 – ident: ref72 doi: 10.1016/S0016-5085(17)34357-3 – ident: ref62 doi: 10.1136/gutjnl-2018-BSGAbstracts.106 – ident: ref2 doi: 10.1056/NEJMoa050516 – ident: ref83 doi: 10.1111/bph.13476 – ident: ref71 doi: 10.1016/S0140-6736(16)32537-5 – ident: ref12 doi: 10.1016/S0140-6736(02)08512-4 – ident: ref57 doi: 10.1016/j.cgh.2014.01.029 – ident: ref14 doi: 10.1038/ajg.2010.392 – ident: ref45 doi: 10.5217/ir.2017.15.4.475 – ident: ref49 – ident: ref80 doi: 10.1016/j.autrev.2017.03.007 – ident: ref22 doi: 10.2174/13894501113146660206 – ident: ref53 doi: 10.1136/gutjnl-2016-312912 – ident: ref24 doi: 10.3389/fimmu.2017.00891 – ident: ref32 doi: 10.1056/NEJMoa1215734 – ident: ref28 doi: 10.1056/NEJMoa051782 – ident: ref84 doi: 10.1056/NEJMoa1513248 – ident: ref43 – ident: ref47 doi: 10.1111/bjd.12214 – ident: ref94 doi: 10.1016/S0140-6736(89)91183-5 – ident: ref20 doi: 10.1002/14651858.CD000067.pub3 – ident: ref61 doi: 10.1016/S0140-6736(14)60661-9 – ident: ref52 doi: 10.1111/j.1600-065X.2008.00754.x – ident: ref98 doi: 10.1080/14712598.2016.1177019 – ident: ref6 doi: 10.1053/j.gastro.2005.11.030 – ident: ref3 doi: 10.1136/gut.2010.221127 – ident: ref46 doi: 10.1111/apt.14794 – ident: ref88 doi: 10.1053/j.gastro.2013.10.052 – ident: ref75 doi: 10.1053/j.gastro.2006.09.016 – ident: ref27 doi: 10.1001/archneur.65.12.noc80051 – ident: ref40 doi: 10.1136/gutjnl-2015-311079 – ident: ref56 doi: 10.1016/j.semarthrit.2016.05.014 – ident: ref77 doi: 10.3390/ijms18061276 – ident: ref100 doi: 10.1016/S0140-6736(16)31203-X – ident: ref97 doi: 10.4166/kjg.2018.71.2.61 – ident: ref39 doi: 10.1016/j.jneuroim.2013.08.011 – ident: ref7 doi: 10.1056/NEJMoa062897 – ident: ref74 doi: 10.1172/JCI12821 – ident: ref48 doi: 10.1111/jdv.13611 – ident: ref58 doi: 10.1136/gutjnl-2016-312735 – ident: ref70 – ident: ref63 doi: 10.1136/gut.2010.226548 – ident: ref91 doi: 10.1016/j.cgh.2018.02.024 – ident: ref99 doi: 10.1001/jama.2015.16700 – ident: ref25 doi: 10.1056/NEJMoa043335 – ident: ref95 doi: 10.1093/ecco-jcc/jjx063 – ident: ref44 doi: 10.1056/NEJMoa1602773 – ident: ref66 doi: 10.1016/S0140-6736(17)30570-6 – ident: ref30 doi: 10.1056/NEJMoa1107829 – ident: ref34 doi: 10.1053/j.gastro.2014.05.008 – ident: ref96 doi: 10.1097/MIB.0000000000001228 – ident: ref38 doi: 10.1093/ecco-jcc/jjw176 – ident: ref29 doi: 10.1056/NEJMoa051847 – ident: ref76 doi: 10.1056/NEJMoa1407250 – ident: ref87 doi: 10.1056/NEJMoa0904492 – ident: ref68 doi: 10.1053/j.gastro.2017.03.049 |
| SSID | ssj0061275 |
| Score | 2.5215182 |
| SecondaryResourceType | review_article |
| Snippet | New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize... New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-totarget algorithms in order to optimize... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 604 |
| SubjectTerms | colitis crohn disease Fecal Microbiota Transplantation Humans inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Review Stem Cell Transplantation therapy ulcerative 내과학 |
| Title | Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31195433 https://www.proquest.com/docview/2314575101 https://pubmed.ncbi.nlm.nih.gov/PMC6860034 https://doaj.org/article/8e32d3490d954df48dac75f413aa5516 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002522833 |
| Volume | 13 |
| WOSCitedRecordID | wos000496945500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Gut and Liver, 2019, 13(6), , pp.604-616 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2005-1212 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061275 issn: 1976-2283 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s0WqAxC4hQ1Dz-PFKiogFUPBe3NcvxoV10ctLtt_z4zTrJ0USUunCLFtuSMxzPfZOxvCHkrrfRIQ1WEoMqCScYL7VqIeSyPUnCtfK6i8OOrnE7VbKaPr5X6wjNhPT1wL7h9FZraN0yXXnPmI1PeOskj2F5rMcmD1reUegymehsskLY855OlKJDgpaed5QAo9k_TAp2g3nJEma8f3Etaxpug5t8nJq-5oMMH5P6AHen7fs4Pya2QHpG734bs-GPy5fjPzckV7RIdyJeoTZ5Ou8uwoCfjufIVBbRKj1IEjfiZM-30oLuCHh_7jM0T8v3w08mHz8VQLKFwTNbrQtoWY52oVWRtbaumDVK0WOhc8LaNAFS897xmsVWyDo0H3x4hNHZRlK7GX6FPyU7qUnhOaODWaqc1i9yCyANs8aoKAM0Ca51yfkLejZIzbmASx4IWCwMRBcrYjDKekNebnr969owb-hyg8DftyHedX4AWmEELzL-0YELewNKZczfP4_F52pnzpYGo4MgIwDFgaGA248oa2ESYGbEpdBcrAyCXYQKqrCbkWb_Sm_k0mRSvgdFySwe2JrzdkuZnmahbKIH8P7v_4wtfkHuA1TReg6z4S7KzXl6EV-SOu1zPV8s9clvO1F7eA78B6jsKJw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perspectives+on+Current+and+Novel+Treatments+for+Inflammatory+Bowel+Disease&rft.jtitle=Gut+and+liver&rft.au=Na%2C+Soo-Young&rft.au=Moon%2C+Won&rft.date=2019-11-15&rft.issn=2005-1212&rft.eissn=2005-1212&rft.volume=13&rft.issue=6&rft.spage=604&rft_id=info:doi/10.5009%2Fgnl19019&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-2283&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-2283&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-2283&client=summon |